{"DataElement":{"publicId":"13451934","version":"1","preferredName":"Treatment Cohort Study 10217 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10217 in which subsets of a defined population are identified.","longName":"TX_COH_10217_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13451926","version":"1","preferredName":"10217 Cohort Code","preferredDefinition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke)._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"13451926v1.00","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"S1L-1","valueDescription":null,"ValueMeaning":{"publicId":"13451927","version":"1","preferredName":"S1L-1: Copanlisib 45 mg IV D1,15 Olaparib 200mg PO BID","longName":"13451927v1.00","preferredDefinition":"S1L-1: Copanlisib 45 mg IV D1,15 Olaparib 200mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA42412F-D4C0-355F-E053-731AD00AFE42","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA42412F-D4C1-355F-E053-731AD00AFE42","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","deletedIndicator":"No"},{"value":"S1L1","valueDescription":null,"ValueMeaning":{"publicId":"13451928","version":"1","preferredName":"S1L1: Copanlisib 45 mg IV D1,8,15 Olaparib 200mg PO BID","longName":"13451928v1.00","preferredDefinition":"S1L1: Copanlisib 45 mg IV D1,8,15 Olaparib 200mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA424A20-E2F1-365E-E053-731AD00A38D4","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA424A20-E2F3-365E-E053-731AD00A38D4","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","deletedIndicator":"No"},{"value":"S1L2","valueDescription":null,"ValueMeaning":{"publicId":"13451929","version":"1","preferredName":"S1L2: Copanlisib 45 mg IV D1,8,15 Olaparib 300mg PO BID","longName":"13451929v1.00","preferredDefinition":"S1L2: Copanlisib 45 mg IV D1,8,15 Olaparib 300mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA424A20-E2F2-365E-E053-731AD00A38D4","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA424A20-E2F4-365E-E053-731AD00A38D4","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","deletedIndicator":"No"},{"value":"S1L3","valueDescription":null,"ValueMeaning":{"publicId":"13451930","version":"1","preferredName":"S1L3: Copanlisib 60 mg IV D1,8,15 Olaparib 300mg PO BID","longName":"13451930v1.00","preferredDefinition":"S1L3: Copanlisib 60 mg IV D1,8,15 Olaparib 300mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA425539-85EB-37DB-E053-731AD00ABE4F","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA425539-85EE-37DB-E053-731AD00ABE4F","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","deletedIndicator":"No"},{"value":"S1L3A","valueDescription":null,"ValueMeaning":{"publicId":"13451931","version":"1","preferredName":"S1L3A: Copanlisib 60 mg IV D1,15 Olaparib 300mg PO BID","longName":"13451931v1.00","preferredDefinition":"S1L3A: Copanlisib 60 mg IV D1,15 Olaparib 300mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA425539-85EC-37DB-E053-731AD00ABE4F","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA425539-85EF-37DB-E053-731AD00ABE4F","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","deletedIndicator":"No"},{"value":"S2L-1","valueDescription":null,"ValueMeaning":{"publicId":"13451932","version":"1","preferredName":"S2L-1: Copanlisib 45 mg + Olaparib 200mg + Durvalumab 1500 mg","longName":"13451932v1.00","preferredDefinition":"S2L-1: Copanlisib 45 mg + Olaparib 200mg + Durvalumab 1500 mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA425539-85ED-37DB-E053-731AD00ABE4F","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA425539-85F0-37DB-E053-731AD00ABE4F","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","deletedIndicator":"No"},{"value":"S2L1","valueDescription":null,"ValueMeaning":{"publicId":"13451933","version":"1","preferredName":"S2L1: Copanlisib 60 mg + Olaparib 300mg + Durvalumab 1500 mg","longName":"13451933v1.00","preferredDefinition":"S2L1: Copanlisib 60 mg + Olaparib 300mg + Durvalumab 1500 mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA425B33-DCBE-38A8-E053-731AD00A0B76","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA425B33-DCBF-38A8-E053-731AD00A0B76","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-04-26","deletedIndicator":"No"},{"value":"S1L3ASG2","valueDescription":null,"ValueMeaning":{"publicId":"13484611","version":"1","preferredName":"S1L3A: Doublet Expansion DDR","longName":"13484611v1.00","preferredDefinition":"S1L3A: Doublet Expansion DDR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FACCE4C2-2FCB-4047-E053-731AD00A1715","latestVersionIndicator":"Yes","beginDate":"2023-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-03","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FACCE4C2-2FCD-4047-E053-731AD00A1715","beginDate":"2023-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-03","modifiedBy":"SOKKERL","dateModified":"2023-05-03","deletedIndicator":"No"},{"value":"S1L3ASG3","valueDescription":null,"ValueMeaning":{"publicId":"13484612","version":"1","preferredName":"S1L3A: Doublet Expansion PIK3CA or PTEN","longName":"13484612v1.00","preferredDefinition":"S1L3A: Doublet Expansion PIK3CA or PTEN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FACCE4C2-2FCC-4047-E053-731AD00A1715","latestVersionIndicator":"Yes","beginDate":"2023-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-03","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FACCE4C2-2FCE-4047-E053-731AD00A1715","beginDate":"2023-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-05-03","modifiedBy":"SOKKERL","dateModified":"2023-05-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12290815","version":"1","preferredName":"Cohort Study Code","preferredDefinition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke)._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"12290815v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F175D1B5-0035-7223-E053-731AD00A1661","latestVersionIndicator":"Yes","beginDate":"2023-01-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-01-04","modifiedBy":"SOKKERL","dateModified":"2023-01-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA422935-2CCB-3221-E053-731AD00A900F","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeDescription":null,"administrativeNotes":"5/3/2023 added 2 new PVs and ALTVM and Value descriptions per ticket request CADSR0002386. ls","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Please select the cohort","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA427185-1CF1-3EE6-E053-731AD00A8118","latestVersionIndicator":"Yes","beginDate":"2023-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-04-26","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeDescription":null,"administrativeNotes":"4/26/2023 curated for cohort study 10217 ls.","unresolvedIssues":null,"deletedIndicator":"No"}}